The effectiveness of extracorporeal shock wave therapy and wrist splint for management of carpal tunnel syndrome

The effectiveness of extracorporeal shock wave therapy and wrist splint versus wrist splint for management of carpal tunnel syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014083118991N1

Enrollment

Registered

2014-10-16

Start date

2014-10-08

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carpal tunnel syndrome. carpal tunnel syndrome

Interventions

Intervention 1: intervention : ESWT receive in 3 sessions once a week. each patient receive ESWT over median nerve at carpal tunnel while the patient's forearm is placed on the table with the palm fac

Treatment - Devices

Treatment - Other

control:patients of control group receive wrist night splint in a neutral position with ergonomic training including avoidance of repeated and extreme wrist movements for 12 weeks.

intervention : ESWT receive in 3 sessions once a week. each patient receive ESWT over median nerve at carpal tunnel while the patient's forearm is placed on the table with the palm facing up with this

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients 18-70 years of age; tingling and numbness or hand pain more than 1 month; vas equal or more than 4; positive tinel's sign or phalen's test; confirmed mild to moderate carpal tunnel syndrome by electrophysiological study. Exclusion criteria: severe carpal tunnel syndrome; pregnancy; previous carpal tunnel decompression surgery in affected hand; corticosteroid injection to the carpal tunnel within last 3 months; history of wrist fracture in affected hand; abnormal EDX findings except carpal tunnel syndrome such as radiculopathy or polyneuropathy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Tingling and pain intensity. Timepoint: before beginning treatment, 3, 8 and 12 weeks after treatment. Method of measurement: visual analog scale.;Severity of symptoms and functional status. Timepoint: before beginning treatment, 3, 8 and 12 weeks after treatment. Method of measurement: persian quick DASH questionnaire.;Sensory and motor distal latency and amplitude of median nerve. Timepoint: Before beginning treatment, 3, 8 and 12 weeks after treatment. Method of measurement: EDX evaluating (nerve Conduction Study).	—

Measure

Time frame

Tingling and pain intensity. Timepoint: before beginning treatment, 3, 8 and 12 weeks after treatment. Method of measurement: visual analog scale.;Severity of symptoms and functional status. Timepoint: before beginning treatment, 3, 8 and 12 weeks after treatment. Method of measurement: persian quick DASH questionnaire.;Sensory and motor distal latency and amplitude of median nerve. Timepoint: Before beginning treatment, 3, 8 and 12 weeks after treatment. Method of measurement: EDX evaluating (nerve Conduction Study).

—

Secondary

Measure	Time frame
Any side effect after intervention. Timepoint: during ESWT therapy, 3, 8 and 12 weeks after therapy. Method of measurement: Ask from patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Ghazaei

Iran University Of Medical Science

fateme_ghazaei@yahoo.com+98 21 8214 1679

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026